Loading organizations...
§ Private Profile · Somerville, MA, USA
Develops orally administered microbiome therapeutics for gastrointestinal and systemic diseases, using machine learning.
Based in Somerville, Massachusetts, Finch Therapeutics develops orally administered microbiome therapeutics using machine learning algorithms to reverse engineer successful microbiota transplantations for gastrointestinal and systemic diseases. The clinical-stage biotechnology company targets conditions such as recurrent C. difficile infection, inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B. Operating with approximately 75 employees, the firm holds over 70 issued patents and 140 pending applications while collaborating with pioneer Dr. Thomas Borody and the Centre for Digestive Diseases. Following the discontinuation of its Phase 3 trial for CP101 in 2023, the enterprise shifted focus toward monetizing its extensive intellectual property estate and subsequently delisted from the Nasdaq exchange in October 2024. Finch Therapeutics was founded in 2014 by a team of graduates from MIT who previously established OpenBiome, later expanding its technological foundation through a merger with Crestovo.
Finch Therapeutics has raised $189.0M across 4 funding rounds.
Finch Therapeutics has raised $189.0M in total across 4 funding rounds.
Finch Therapeutics has raised $189.0M in total across 4 funding rounds.
Finch Therapeutics's investors include Avenir, Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave Group, OCV Partners, Nick Haft, Shumway Capital, SIG, SymBiosis, Trans-Pacific Technology Fund.
Finch Therapeutics has raised $189.0M across 4 funding rounds. Most recently, it raised $90.0M Series D in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 17, 2020 | $90M Series D | — | Avenir, Baupost Group, Humboldt Fund, MSD Capital, MSD Partners, Octave Group, OCV Partners, Nick Haft, Shumway Capital, SIG, SymBiosis, Trans Pacific Technology Fund, Willett Advisors | Announced |
| Aug 22, 2019 | $53M Series C | — | Avenir, Morgan Noble Healthcare Partners, OCV Partners, Shumway Capital, Susquehanna International Group, SymBiosis, Trans Pacific Technology Fund, Willett Advisors | Announced |
| Mar 1, 2018 | $36M Series B | — | Avenir, Morgan Noble Healthcare Partners, Chris Shumway, Willett Advisors | Announced |
| Apr 6, 2017 | $10M Venture Round | Takeda | — | Announced |